56. Behcet disease Clinical trials / Disease details

Clinical trials : 81 / Drugs : 107 - (DrugBank : 30) / Drug target genes : 36 - Drug target pathways : 116

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000012469	2013/12/02	02/12/2013	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study	Intestinal Behcet's disease	Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously. Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately	Castle Study Group	NULL	Recruiting	15years-old	Not applicable	Male and Female	50	Not selected	Japan
2	NCT00931957 (ClinicalTrials.gov)	October 2010	30/6/2009	Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease	Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease	Behcet Syndrome;Uveal Disease	Drug: Etanercept , Methotrexate, Prednisolone	Tehran University of Medical Sciences	Wyeth is now a wholly owned subsidiary of Pfizer	Recruiting	16 Years	60 Years	Both	80	N/A	Iran, Islamic Republic of